5/0.5 mg/ml semaglutide FlexNetIq Diabetes Medicine - OSEPTIN 0.25

After the Gold Rush: What Comes Next for GLP-1s Inside the post-compounding GLP-1 market: pharmas pivot, DTCs ceiling, and payer infrastructure at scale

You could be injecting a solution that has lost 30%, 50%, or even more of its potency without knowing it

You are currently undergoing chemotherapy or radiation therapy (antioxidants can sometimes interfere with these treatments)

Given the study did not show a significant difference in fibrosis stage, semaglutide has not yet been FDA approved for NASH

The addition of AMPLITUDE-O data refined evidence for cardiovascular benefits, in particular showing reduction in hospital admission for heart failure, and suggested exendin-4-based compounds lower risks as well as human-based GLP-1 receptor agonists, Naveed Sattar, MD, PhD, professor of metabolic medicine at the University of Glasgow in the U.K., and colleagues wrote